山东大学耳鼻喉眼学报 ›› 2023, Vol. 37 ›› Issue (6): 68-74.doi: 10.6040/j.issn.1673-3770.0.2023.169

• 名师特稿 • 上一篇    下一篇

脂质代谢标志物在早期筛查阻塞性睡眠呼吸暂停患者中阿尔兹海默症的应用价值

王璐,张云云,郭华,崔小川   

  1. 南京医科大学无锡医学中心/南京医科大学附属无锡市人民医院 全科医学科, 江苏 无锡 214023
  • 发布日期:2023-12-15
  • 通讯作者: 崔小川. E-mail:cuixiaochuan@njmu.edu.cn
  • 基金资助:
    无锡市卫健委“双百”中青年医疗卫生拔尖人才课题项目(BJ2020008)

Application value of lipid metabolism markers for the early screening of Alzheimer's disease in obstructive sleep apnea patients

WANG Lu, ZHANG Yunyun, GUO Hua, CUI Xiaochuan   

  1. Department of General Medicine, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu, China
  • Published:2023-12-15

PDF (PC)

246

摘要： 阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnoea, OSA)是一种常见的临床疾病,其特征是慢性间歇性缺氧和睡眠片段化,可导致多器官、多系统功能障碍。OSA可增加阿尔兹海默症(Alzheimer's disease, AD)的风险,同时可导致脂质代谢的异常,而脂质代谢异常也是AD重要的发病机制。从胆固醇代谢、磷脂类代谢、脂蛋白类代谢、载脂蛋白类代谢对OSA的脂质代谢异常的标志物及其可能参与AD的起病及进展进行综述,有助于筛选OSA增加AD风险的早期评估指标,为临床探索生物标志物构建理论依据。

关键词: 阻塞性睡眠呼吸暂停, 阿尔兹海默症, 脂质代谢, 生物标志物, 间歇性缺氧

Abstract: Obstructive sleep apnea(OSA)is a common clinical condition characterized by chronic intermittent hypoxia and sleep fragmentation, which can lead to multi-organ and multi-system dysfunction. Prior research has shown that OSA can increase the risk of Alzheimer's disease(AD), and can also trigger abnormal lipid metabolism, an important pathogenic feature of AD. In this review, we discuss the markers of abnormal lipid metabolism of OSA, discussing the possible involvement of cholesterol, phospholipid, lipoprotein and apolipoprotein metabolism in the onset and progression of Alzheimer's disease. This knowledge will be helpful in the screening of early evaluation indicators of OSA which increase the risk of AD. Further, this knowledge can be used to construct a theoretical basis for the clinical exploration of relevant biomarkers.

Key words: Obstructive sleep apnea, Alzheimer's disease, Lipid metabolism, Biomarkers, Intermittent hypoxia

中图分类号: 

  • R56
[1] Morsy NE, Farrag NS, Zaki NFW, et al. Obstructive sleep apnea: personal, societal, public health, and legal implications[J]. Rev Environ Health, 2019, 34(2): 153-169. doi:10.1515/reveh-2018-0068
[2] Bubu OM, Andrade AG, Umasabor-Bubu OQ, et al. Obstructive sleep apnea, cognition and Alzheimer's disease: a systematic review integrating three decades of multidisciplinary research[J]. Sleep Med Rev, 2020, 50: 101250. doi:10.1016/j.smrv.2019.101250
[3] 朱英超, 吴晴伟, 许晨婕, 等. 阻塞性睡眠呼吸暂停低通气综合征患者认知功能障碍现状调查及与生活质量的相关性研究[J]. 现代生物医学进展, 2022, 22(16): 3036-3040. doi:10.13241/j.cnki.pmb.2022.16.008 ZHU Yingchao, WU Qingwei, XU Chenjie, et al. Status survey of cognitive impairment in patients with obstructive sleep apnea hypopnea syndrome and its correlation with quality of life[J]. Progress in Modern Biomedicine, 2022, 22(16): 3036-3040. doi:10.13241/j.cnki.pmb.2022.16.008
[4] Zabel M, Nackenoff A, Kirsch WM, et al. Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: a meta-analysis in human pathological specimens[J]. Free Radic Biol Med, 2018, 115: 351-360. doi:10.1016/j.freeradbiomed.2017.12.016
[5] Schrag M, Mueller C, Zabel M, et al. Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis[J]. Neurobiol Dis, 2013, 59: 100-110. doi:10.1016/j.nbd.2013.07.005
[6] Turner AD, Locklear CE, Oruru D, et al. Exploring the combined effects of sleep apnea and APOE-e4 on biomarkers of Alzheimer's disease[J]. Front Aging Neurosci, 2023, 14: 1017521. doi:10.3389/fnagi.2022.1017521
[7] Barros D, García-Río F. Obstructive sleep apnea and dyslipidemia: from animal models to clinical evidence[J]. Sleep, 2019, 42(3): zsy236. doi:10.1093/sleep/zsy236
[8] Casas-Fernández E, Peña-Bautista C, Baquero M, et al. Lipids as early and minimally invasive biomarkers for Alzheimer's disease[J]. Curr Neuropharmacol, 2022, 20(8): 1613-1631. doi:10.2174/1570159X19666211102150955
[9] Kao YC, Ho PC, Tu YK, et al. Lipids and Alzheimer's disease[J]. Int J Mol Sci, 2020, 21(4): 1505. doi:10.3390/ijms21041505
[10] Agarwal M, Khan S. Plasma lipids as biomarkers for Alzheimer's disease: a systematic review[J]. Cureus, 2020, 12(12): e12008. doi:10.7759/cureus.12008
[11] Li J, Nanayakkara A, Jun J, et al. Effect of deficiency in SREBP cleavage-activating protein on lipid metabolism during intermittent hypoxia[J]. Physiol Genomics,2007,31(2):273-280.doi: 10.1152/physiolgenomics.00082.2007
[12] Agarwal M, Khan S. Plasma lipids as biomarkers for Alzheimer's disease: a systematic review[J]. Cureus, 2020, 12(12): e12008. doi:10.7759/cureus.12008
[13] Kelicen P, Nordberg A. Feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells[J]. Cell Mol Neurobiol, 2006, 26(3): 225-235. doi:10.1007/s10571-006-9060-x
[14] Astarita G, Jung KM, Vasilevko V, et al. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease[J]. PLoS One, 2011, 6(10): e24777. doi:10.1371/journal.pone.0024777
[15] Xu RY, Huang R, Xiao Y, et al. Attenuated macrophage cholesterol efflux function in patients with obstructive sleep apnea-hypopnea syndrome[J]. Sleep Breath, 2015, 19(1): 369-375. doi:10.1007/s11325-014-1030-9
[16] Bossaerts L, Cacace R, Van Broeckhoven C. The role of ATP-binding cassette subfamily A in the etiology of Alzheimer's disease[J]. Mol Neurodegener, 2022, 17(1): 31. doi:10.1186/s13024-022-00536-w
[17] Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, et al. The role of the ATP-binding cassette A1(ABCA1)in human disease[J]. Int J Mol Sci, 2021, 22(4): 1593. doi:10.3390/ijms22041593
[18] Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron[J]. 2008,58(5):681-693.doi:10.1016/j.neuron.2008.04.010
[19] Zappelli E, Daniele S, Ceccarelli L, et al. α-Glyceryl-phosphoryl-ethanolamine protects human hippocampal neurons from ageing-induced cellular alterations[J]. Eur J Neurosci, 2022, 56(5): 4514-4528. doi:10.1111/ejn.15783
[20] Dakterzada F, Benítez ID, Targa A, et al. Blood-based lipidomic signature of severe obstructive sleep apnoea in Alzheimer's disease[J]. Alzheimers Res Ther, 2022, 14(1): 163. doi:10.1186/s13195-022-01102-8
[21] Alberghina M, Giuffrida AM. Effect of hypoxia on the incorporation of[2-3H] glycerol and[1-14C [-palmitate into lipids of various brain regions[J]. J Neurosci Res, 1981, 6(3): 403-419. doi:10.1002/jnr.490060315
[22] Kawai M, Kirkness JP, Yamamura S, et al. Increased phosphatidylcholine concentration in saliva reduces surface tension and improves airway patency in obstructive sleep apnoea[J]. J Oral Rehabil, 2013, 40(10): 758-766. doi:10.1111/joor.12094
[23] Liu TT, Pang SJ, Jia SS, et al. Association of plasma phospholipids with age-related cognitive impairment: results from a cross-sectional study[J]. Nutrients, 2021, 13(7): 2185. doi:10.3390/nu13072185
[24] Song S, Cheong LZ, Man QQ, et al. Characterization of potential plasma biomarkers related to cognitive impairment by untargeted profiling of phospholipids using the HILIC-ESI-IT-TOF-MS system[J]. Anal Bioanal Chem, 2018, 410(12): 2937-2948. doi:10.1007/s00216-018-0975-0
[25] Gündüz C, Basoglu OK, Hedner J, et al. Obstructive sleep apnoea independently predicts lipid levels: data from the European Sleep Apnea Database[J]. Respirol Carlton Vic, 2018, 23(12): 1180-1189. doi:10.1111/resp.13372
[26] Nadeem R, Singh M, Nida M, et al. Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis[J]. J Clin Sleep Med, 2014, 10(5): 475-489. doi:10.5664/jcsm.3690
[27] Iqbal G, Braidy N, Ahmed T. Blood-based biomarkers for predictive diagnosis of cognitive impairment in a Pakistani population[J]. Front Aging Neurosci, 2020, 12: 223. doi:10.3389/fnagi.2020.00223
[28] Sáiz-Vazquez O, Puente-Martínez A, Ubillos-Landa S, et al. Cholesterol and Alzheimer's disease risk: a meta-meta-analysis[J]. Brain Sci, 2020, 10(6): 386. doi:10.3390/brainsci10060386
[29] Marsillach J, Adorni MP, Zimetti F, et al. HDL proteome and Alzheimer's disease: evidence of a link[J]. Antioxidants, 2020, 9(12): 1224. doi:10.3390/antiox9121224
[30] Button EB, Robert J, Caffrey TM, et al. HDL from an Alzheimer's disease perspective[J]. Curr Opin Lipidol, 2019, 30(3): 224-234. doi:10.1097/MOL.0000000000000604
[31] Bruce KD, Tang MP, Reigan P, et al. Genetic variants of lipoprotein lipase and regulatory factors associated with Alzheimer’s disease risk[J]. Int J Mol Sci, 2020, 21(21): 8338. doi:10.3390/ijms21218338
[32] 吕圆, 王姝之, 戴斌, 等. 脂蛋白脂肪酶在神经系统研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1041-1048. doi:10.12092/j.issn.1009-2501.2022.09.011 LÜ Yuan, WANG Shuzhi, DAI Bin, et al. New advances in nervous system of lipoprotein lipase[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1041-1048. doi:10.12092/j.issn.1009-2501.2022.09.011
[33] 李洁, 张艳林, 王婧, 等. 阻塞性睡眠呼吸暂停综合征患者血清中脂蛋白脂肪酶水平与脂代谢紊乱的相关性[J]. 中华医学杂志, 2014, 94(6): 403-407. doi:10.3760/cma.j.issn.0376-2491.2014.06.002 LI Jie, ZHANG Yanlin, WANG Jing, et al. Association between serum lipoprotein lipase level and dyslipidemia in patients with obstructive sleep apnea syndrome[J]. National Medical Journal of China, 2014, 94(6): 403-407. doi:10.3760/cma.j.issn.0376-2491.2014.06.002
[34] Bruce KD, Tang MP, Reigan P, et al. Genetic variants of lipoprotein lipase and regulatory factors associated with Alzheimer's disease risk[J]. Int J Mol Sci, 2020, 21(21): 8338. doi:10.3390/ijms21218338
[35] Loving BA, Bruce KD. Lipid and lipoprotein metabolism in microglia[J]. Front Physiol, 2020, 11: 393. doi:10.3389/fphys.2020.00393
[36] Jeong W, Lee H, Cho S, et al. ApoE4-induced cholesterol dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer's disease[J]. Mol Cells, 2019, 42(11): 739-746. doi:10.14348/molcells.2019.0200
[37] Therriault J, Benedet AL, Pascoal TA, et al. Alzheimer's disease neuroimaging initiative APOEε4 potentiates the relationship between amyloid-β and tau pathologies[J]. Mol Psychiatry, 2021,26(10):5977-5988. doi:10.1038/s41380-020-0688-6
[38] O'Hara R, Schröder CM, Kraemer HC, et al. Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers[J]. Neurology, 2005, 65(4): 642-644. doi:10.1212/01.wnl.0000173055.75950.bf
[39] Cosentino FI, Bosco P, Drago V, et al. The APOE epsilon4 allele increases the risk of impaired spatial working memory in obstructive sleep apnea[J]. Sleep Med, 2008, 9(8): 831-839. doi:10.1016/j.sleep.2007.10.015
[40] Huang YD, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases[J]. Neurobiol Dis, 2014, 72(Pt A): 3-12. doi:10.1016/j.nbd.2014.08.025
[41] Lim AS, Yu L, Kowgier M, et al. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep[J]. JAMA Neurol, 2013, 70(12): 1544-1551. doi:10.1001/jamaneurol.2013.4215
[42] Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20(1): 68-80. doi:10.1016/S1474-4422(20)30412-9
[43] Wei WR, Wang KR, Shi JY, et al. The relationship between sleep disturbance and apolipoprotein E ε4 in adults with mild cognitive impairment and Alzheimer's disease dementia: an integrative review[J]. Biol Res Nurs, 2022, 24(3): 327-337. doi:10.1177/10998004221081044
[44] Yi MH, Tan Y, Pi YZ, et al. Variants of candidate genes associated with the risk of obstructive sleep apnea[J]. Eur J Clin Invest, 2022, 52(1): e13673. doi:10.1111/eci.13673
[45] Xu HJ, Qian YJ, Guan J, et al. No association between the ApoE ε2 and ε4 alleles and the risk of obstructive sleep apnea: a systematic review and meta-analysis[J]. Biomed Rep, 2015, 3(3): 313-318. doi:10.3892/br.2015.425
[46] Qian J, Betensky RA, Hyman BT, et al. Association of APOE genotype with heterogeneity of cognitive decline rate in alzheimer disease[J]. Neurology, 2021, 96(19): e2414-e2428. doi:10.1212/WNL.0000000000011883
[47] Paula-Lima AC, Tricerri MA, Brito-Moreira J, et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity[J]. Int J Biochem Cell Biol, 2009, 41(6): 1361-1370. doi:10.1016/j.biocel.2008.12.003
[48] Lewis TL, Cao DF, Lu HL, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of alzheimer disease[J]. J Biol Chem, 2010, 285(47): 36958-36968. doi:10.1074/jbc.M110.127829
[49] Leduc V, Jasmin-Bélanger S, Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease[J]. Trends Mol Med, 2010, 16(10): 469-477. doi:10.1016/j.molmed.2010.07.008
[50] Li X, Ma YF, Wei X, et al. Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta[J]. Neurosci Bull, 2014, 30(1): 162-168. doi:10.1007/s12264-013-1391-2
[51] Peng Y, Zhou L, Cao Y, et al. Relation between serum leptin levels, lipid profiles and neurocognitive deficits in Chinese OSAHS patients[J]. Int J Neurosci, 2017,127(11):981-987. doi: 10.1080/00207454.2017.1286654
[52] Namba Y, Tsuchiya H, Ikeda K. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease[J]. Neurosci Lett, 1992, 134(2): 264-266. doi:10.1016/0304-3940(92)90531-b
[53] Kuo YM, Emmerling MR, Bisgaier CL, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain aβ 1-42 levels[J]. Biochem Biophys Res Commun, 1998, 252(3): 711-715. doi:10.1006/bbrc.1998.9652
[54] Hu H, Tan L, Bi YL, et al. Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology[J]. Ann Clin Transl Neurol, 2020, 7(10): 1766-1778. doi:10.1002/acn3.51153
[55] Fadaei R, Mohassel Azadi S, Rhéaume E, et al. High-density lipoprotein cholesterol efflux capacity in patients with obstructive sleep apnea and its relation with disease severity[J]. Lipids Health Dis, 2022, 21(1): 116. doi:10.1186/s12944-022-01723-w
[56] Zhang WD, Hu CY, Yang Z, et al. APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease[J]. Neural Regen Res, 2014, 9(6): 653. doi:10.4103/1673-5374.130117
[1] 吉睿,刘雅洁,王佳琪,史雅文,张炜明,殷敏. 慢性间歇性缺氧对大鼠茎突舌肌的影响及作用机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 44-48.
[2] 孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.
[3] 熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167.
[4] 王盛,李银丹,杨金姬. microRNA在鼻咽癌中的作用及其研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 125-131.
[5] 卫志成,彭裕,沈力,李莉琳,沈杭东,李馨仪,许华俊,关建. 犬尿氨酸介导阻塞性睡眠呼吸暂停所致肝功能损伤:一项横断面研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 38-44.
[6] 马馨,董凌康,吴红敏,易红良,邹建银. 外展悬吊缝合技术在阻塞性睡眠呼吸暂停治疗中的改良及应用进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 81-88.
[7] 李莉琳,李馨仪,关建. 阻塞性睡眠呼吸暂停与抑郁症共病机制的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 89-96.
[8] 王小清,王钰彧,仇金玮,许金侠,朱梅. 口面肌功能训练对鼾声患者鼾声指标及睡眠质量的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 101-107.
[9] 周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176.
[10] 刘莲莲,李进让. 阻塞性睡眠呼吸暂停与咽喉反流[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 15-22.
[11] 张杉,陈秋,周方伟,马亦飞. 生物标志物在咽喉反流性疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(6): 46-54.
[12] 罗露,周恩,肖旭平,林志强,方志杰,吕晓虹. 等离子点状激发技术在儿童OSA扁桃体腺样体切除术联合围手术期快速康复中的应用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 26-30.
[13] 赵云,滕支盼,李琦,沈小飞. 儿童腺样体扁桃体切除后圆枕增生26例[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 43-48.
[14] 王桂芳,李仁高,马青. H-UPPP联合低温等离子舌根射频消融术对OSAHS患者血氧饱和度及动脉血氧分压的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 49-54.
[15] 任晓勇. 阻塞性睡眠呼吸暂停合并症的研究现状和未来展望[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 1-5.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发